The fibrosis marker galectin-3 and outcome in the general population

Journal of Internal Medicine

Volumn 272, Issue 1, 2012, Pages 55-64

  de Boer, R A ^a   van Veldhuisen, D J ^a   Gansevoort, R T ^a   Muller Kobold, A C ^a   van Gilst, W H ^a   Hillege, H L ^a   Bakker, S J L ^a   van der Harst, P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Biomarkers; Cardiovascular system; Galectin 3; General population; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; LIPID;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; FIBROSIS; GALECTIN 3; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; KIDNEY; LIPIDS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; NEOPLASMS; ODDS RATIO; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 84862640503     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02476.x     Document Type: Article

References (36)

1. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760: 616-35.
2. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008; 13: e17-39.
3. Dhirapong A, Lleo A, Leung P, Gershwin ME, Liu FT. The immunological potential of galectin-1 and -3. Autoimmun Rev 2009; 8: 360-3.
4. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009; 230: 160-71.
5. Califice S, Castronovo V, Van Den Brûle F. Galectin-3 and cancer. Int J Oncol 2004; 25: 983-92.
6. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J 2004; 19: 543-9.
7. Lee YJ, Kang SW, Song JK et al. Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity. Clin Exp Rheumatol 2007; 25: S41-5.
8. Weigert J, Neumeier M, Wanninger J et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 1404-11.
9. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11: 811-7.
10. van Kimmenade RR, Januzzi Jr JL, Ellinor PT et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-24.
11. Lok DJ, Van Der Meer P, de la Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010; 99: 323-8.
12. De Boer RA, Lok JA, Jaarsma T et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43: 60-8.
13. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000; 6: 1389-93.
14. Saussez S, Lorfevre F, Lequeux T et al. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol 2008; 44: 86-93.
15. Hillege HL, Janssen WM, Bak AA et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-26.
16. Linssen GC, Bakker SJ, Voors AA et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 2010; 31: 120-7.
17. Christenson RH, Duh SH, Wu AH et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 2010; 43: 683-90.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatininee: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
19. Bowers SL, Banerjee I, Baudino TA. The extracellular matrix: at the center of it all. J Mol Cell Cardiol 2010; 48: 474-82.
20. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002; 91: 1103-13.
21. Hewitson TD. Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol 2009; 296: F1239-44.
22. el Nahas AM, Muchaneta-Kubara EC, Essawy M, Soylemezoglu O. Renal fibrosis: insights into pathogenesis and treatment. Int J Biochem Cell Biol 1997; 29: 55-62.
23. Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-8.
24. Liu YH, D'Ambrosio M, Liao TD et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009; 296: H404-12.
25. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172: 288-98.
26. Okamura DM, Pasichnyk K, Lopez-Guisa JM et al. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 2011; 300: F245-53.
27. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006; 103: 5060-5.
28. Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T, Kanayama HO. Serum level of galectin-3 in human bladder cancer. J Med Invest 2008; 55: 127-32.
29. Chiu CG, Strugnell SS, Griffith OL et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010; 176: 2067-81.
30. Chauhan D, Li G, Podar K et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005; 65: 8350-8.
31. Udelson JE, Konstam MA. Ventricular remodeling: fundamental to the progression (and regression) of heart failure. J Am Coll Cardiol 2011; 57: 1477-9.
32. Piro M, Della Bona R, Abbate A, Biasucci LM, Crea F. Sex-related differences in myocardial remodeling. J Am Coll Cardiol 2010; 55: 1057-65.
33. Dickstein K, Cohen-Solal A, Filippatos G et al. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.
34. Kadrofske MM, Openo KP, Wang JL. The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch Biochem Biophys 1998; 349: 7-20.
35. Arar C, Gaudin JC, Capron L, Legrand A. Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett 1998; 430: 307-11.
36. Paron I, Scaloni A, Pines A et al. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun 2003; 302: 545-53.